{"entity":{"id":"nct05226871","kind":"trial","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","aka":[],"tldr":"A phase 2 trial of Palbociclib, Cetuximab and Fulvestrant in head and neck squamous cell carcinoma, run by Pfizer, active and no longer recruiting.","summary":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies is a phase 2 interventional study registered as NCT05226871 by Pfizer, with 35 participants enrolled, started 2022-07-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Palbociclib, Cetuximab, Fulvestrant and Letrozole.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05226871","url":"https://clinicaltrials.gov/study/NCT05226871"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["palbociclib","cetuximab","fulvestrant"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05226871","phase":"2","setting":"A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES","sponsor":"Pfizer","enrolled":35,"outcomes":[]},"route":"/trials/nct05226871/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}